University of Pittsburgh, Children’s Hospital of Philadelphia, and Texas Tech University Health Sciences Center researchers have developed a humanized mouse antibody capable of binding to the cell surface receptor GDNF family receptor alpha 2 (GFRA2). These neurotrophic factors are highly expressed in the majority of neuroblastoma (NB) and Ewing sarcoma (ES) tumors and cell lines with a correlation between GFRA2 expression and poor prognosis. The development of antibodies that can specifically bind to GFRA2 could lead to targeted therapies including antibody drug conjugates (ADCs), chimeric antigen receptor (CAR T), and bispecific antibody therapy to treat patients with NB or ES.
